Healthcare / BiotechnologyNasdaqGM
$3.42
-0.10 (-2.71%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-71.3M · quality 68.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
24/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$355M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-212.2%
↓Gross Margin
N/A
•Debt/Equity
0.05
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2012–2025 · 13 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.68x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-165.7M · FCF $-113.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||
| Revenue | — | — | — | — | — | — | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | $-165.7M | $-165.7M | $-80.6M | $-36.9M | $-35.4M | $-50.6M | $-42.5M | $-23.1M | $-61.4M | $-52.0M | $-57.9M | $-74.3M | $-36.5M | $-14.0M | $-13.9M |
| EBITDA | $-172.1M | $-172.1M | $-90.6M | $-41.4M | $-36.2M | — | — | — | — | — | — | — | — | — | — |
| EPS | -2.27 | -2.27 | -1.32 | -0.84 | -1.37 | -2.95 | -3.57 | — | — | — | — | — | — | — | — |
| Balance Sheet | |||||||||||||||
| Debt/Equity | 0.05 | 0.05 | 0.03 | 0.07 | 0.05 | — | — | -20.96 | 6.86 | 0.26 | 0.03 | — | — | — | — |
| Current Ratio | 4.29 | 4.29 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||||
| Free Cash Flow | $-113.3M | $-113.3M | $-71.3M | $-33.6M | $-27.7M | $-42.4M | $-42.3M | $-22.8M | $-51.6M | $-43.8M | $-52.6M | — | — | — | — |
| Returns | |||||||||||||||
| ROE | -212.2% | -212.2% | -46.9% | -45.2% | -31.9% | -78.6% | -47.4% | 3333.1% | -2106.0% | -66.5% | -47.5% | -43.9% | -34.9% | 20.5% | 25.4% |
| Valuation | |||||||||||||||
| P/B | 3.19 | 3.19 | 1.49 | 2.51 | 0.98 | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||||
| EPS Growth | -72.0% | -72.0% | -57.1% | 38.7% | — | 17.4% | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+54.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.32 → -2.27
Residual
+54.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.